SulfaCleanse

Quick links to important sections

SulfaCleanse

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of SulfaCleanse

Quick Facts

Property Description
Active ingredient Sulfacetamide, Sulfur
Form Topical Suspension, Lotion, or Wash
Pharmacological class Topical Anti-infective, Keratolytic Agent
General purpose Management of microbial proliferation and skin scaling
Origin Synthetic (Sulfacetamide) and Elemental/Derived (Sulfur)

What Type of Medicine is SulfaCleanse?

SulfaCleanse is fundamentally a prescription combination product and a specialized dermatological preparation intended for topical administration. Its unique dual identity, which is clinically recognized for its effectiveness, classifies it as both a Topical Anti-infective and a Keratolytic agent. The anti-infective properties are primarily derived from its active ingredient, Sulfacetamide, which is recognized as a synthetic sulfonamide antibiotic. This specific pairing distinguishes it within the market, as the synergistic formulation of a sulfonamide and elemental sulfur offers a comprehensive mechanism often employed in the management of skin conditions characterized by surface inflammation and excessive oil.

Composition, Form, and Dual-Action Purpose

The core of SulfaCleanse is its combination of the active ingredients, Sulfacetamide and Sulfur, typically formulated as a topical suspension, lotion, or wash in an aqueous emulsion base. Sulfacetamide is a synthetic compound that provides antibacterial activity by interfering with bacterial growth processes. The complementary agent, Sulfur, is an elemental substance that provides a notable keratolytic effect, promoting the gentle shedding of the skin’s outer layer, and also offers a mild sebostatic effect that helps moderate oiliness. The overall general purpose of this dual-active formula is to support the health and renewal of the skin surface by controlling bacterial presence and regulating skin cell turnover, a strategy often applied in dermatology for conditions such as seborrheic dermatitis.

Regulatory References

  1. National Library of Medicine DailyMed

What side effects are possible with SulfaCleanse?

Possible Side Effects and Safety Information

The safety profile for this topical combination is formally structured around localized skin reactions and the rare potential for serious systemic effects associated with sulfonamide exposure. The total incidence of adverse reactions in controlled clinical trials for local events has been documented as infrequent, typically less than 2%.

Common and Local Adverse Reactions

The most frequently reported effects involve the Skin and Subcutaneous Tissue Disorders. These reactions are generally local and may include stinging, burning, skin irritation, redness (erythema), and scaling (desquamation). These effects are noted in regulatory labeling as not unusual in the topical treatment of acne.

Serious Systemic Toxicities

Although classified as rare, particularly following topical use, severe systemic toxicities linked to sulfonamide hypersensitivity have been documented. These serious adverse reactions include potentially fatal conditions such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), fulminant hepatic necrosis, and serious Blood and Lymphatic System Disorders such as agranulocytosis and aplastic anemia.

Safety Restrictions and Special Populations

Official labeling defines several high-level safety constraints. The product is contraindicated for individuals with known or suspected hypersensitivity to sulfonamides or sulfur, and for patients with pre-existing kidney disease.

Regulatory documents emphasize that the risk of systemic absorption, and thus the potential for these serious systemic effects, is greater when the product is applied to large, infected, abraded, or denuded skin areas. Safety and effectiveness have not been established in children under the age of 12. Caution is advised for nursing mothers due to the theoretical risk of kernicterus from systemically absorbed sulfonamide.

Overdose and Emergency Response

Overdose Scope

The documented overdose profile for SulfaCleanse is primarily based on the risks associated with large oral overdosage or increased systemic absorption when applied to damaged or extensive skin areas.

Domain Official Regulatory Statements
Documented Overdose Presentations Symptoms include nausea and vomiting. Systemic exposure manifestations include hematuria and crystalluria (precipitation of sulfa crystals in the urine).
Physiological Systems Affected The renal system (kidneys and urinary tract) is the primary system affected due to the risk of crystal formation and subsequent obstruction.
Dose/Exposure Factors Overdose risk increases if the product is applied to large areas, infected, abraded, denuded, or severely burned skin. The product is not to be used by patients with kidney disease due to increased systemic risk.
Emergency-response Statements Emergency treatment should be started immediately. Contact your local Poison Control Center or your doctor.

Official Overdose Statements

  • Overdosage is documented to present with systemic effects, including nausea and vomiting.
  • The official labeling warns of serious renal complications, including crystalluria and the potential for renal shutdown (kidney failure).
  • Regulatory documents mandate that emergency treatment should be started immediately and requires contacting emergency resources.
  • Supportive and symptomatic treatment is the standard documented approach, as a specific antidote is not listed in the official prescribing information.

Connection to the Overdose Profile

Regulatory documents define the overdose profile by focusing on the systemic absorption risks of the sulfonamide component, which can lead to the severe outcome of crystalluria and subsequent renal shutdown. The potential severity of these manifestations dictates the mandatory requirement to seek immediate medical help when overdosage is suspected.

Therapeutic Uses of SulfaCleanse

The product is relevant for the supportive management of common inflammatory facial dermatoses and seborrheic conditions where inflammatory and irritative processes are contributing factors. The product is applied within contexts involving the symptomatic management of acne vulgaris, rosacea, and seborrheic dermatitis. It is used in clinical contexts to help ease the overall symptom load of persistent skin manifestations.


Symptom-Focused Relief

This medication is commonly used in conditions involving acne vulgaris and the papulopustular form of rosacea, as well as seborrheic dermatitis. It is applied to help manage the groups of symptoms characterized by redness, swelling, and the presence of active lesions (papules and pustules), alongside symptoms of excessive oiliness (seborrhea) and flaky patches. The key therapeutic benefit may assist with easing the inflammatory or irritative manifestations, offering symptomatic relief that supports patients during difficult, recurrent episodes.

“This application is relevant for easing symptom clusters that may involve flaking and oiliness, which may help improve day-to-day comfort during symptomatic periods.”


Quick Fact: Supportive Management of Inflammatory Manifestations

Use Context Main Benefit
Recurrent Skin Flares Contributes to maintaining functional stability during recurrent episodes.
Inflammatory Lesions Helps address symptoms related to inflammatory or irritative states.
Seborrheic Symptoms Is applied in addressing symptom clusters of oiliness and flaking.

The product is considered relevant in conditions marked by fluctuating symptom patterns and is often used by adolescent and adult dermatology patients when supportive symptom management is appropriate.

Regulatory References

  1. NIH DailyMed labeling overview

Eligibility and Restrictions for Use

Who Can and Cannot Use SulfaCleanse?

This section describes the population eligibility and restrictions for SulfaCleanse (Sulfacetamide/Sulfur topical combination), based strictly on official regulatory documentation.


Populations for Whom Use is Contraindicated

Use of SulfaCleanse is absolutely contraindicated in patients with the following conditions or known sensitivities:

  • Kidney Disease (Renal Dysfunction).
  • Known or suspected hypersensitivity to Sulfonamides (specifically sulfacetamide) or to Sulfur, or to any other component of the preparation.

Age and Physiological Restrictions

Population Group Regulatory Status
Adults and Adolescents Approved for use (Age 12 and older).
Children Under 12 Safety and effectiveness have not been established.
Pregnancy Conditional Use (Category C). Only if benefit justifies risk.
Nursing Mothers Caution is advised, as excretion into human milk is not known.

Additional Conditional Use

Particular caution is required when applying SulfaCleanse to areas of denuded or abraded skin due to the potential for increased systemic absorption of the active ingredients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interactions documented in regulatory labeling for SulfaCleanse, a topical sulfonamide analog.


Documented Interaction Categories

Interactions are primarily defined by chemical and pharmacodynamic effects at the site of application.

Interacting Product Category Regulatory Statement & Practical Implication
PABA-derivative Local Anesthetics The antibacterial action of SulfaCleanse is antagonized by the p-aminobenzoic acid (PABA) breakdown products of these anesthetics (e.g., Procaine, Tetracaine). Concurrent use must be avoided as efficacy may be lost.
Topical Silver Preparations Chemical incompatibility is documented. Silver salts can inactivate the sulfonamide component of SulfaCleanse. Co-administration should be avoided due to loss of effectiveness.

Systemic Absorption and Interaction Considerations

While the systemic absorption of topical SulfaCleanse is generally minimal, the official labeling includes population-specific warnings tied to potential systemic exposure. Application to large areas, infected, or severely compromised skin may result in increased absorption.

This increased systemic exposure warrants consideration of sulfonamide interaction warnings, particularly concerning the theoretical risk of kernicterus in infants if used by pregnant patients at term or lactating mothers, as detailed in systemic sulfonamide documentation.

Mechanism of Action

How SulfaCleanse Works: Mechanism of Action

SulfaCleanse operates through a complementary dual-action mechanism, engaging two distinct biological pathways to modulate local physiological responses.

Interference with Bacterial Metabolic Growth: The Sulfacetamide component acts as a competitive inhibitor of the bacterial enzyme Dihydropteroate Synthase (DHPS). By structurally mimicking PABA, Sulfacetamide blocks a critical early step in the microbial synthesis of folic acid, a necessary precursor for purine and DNA production. This molecular cascade results in a bacteriostatic effect, inhibiting the growth and replication of susceptible surface microorganisms.

Chemical Modulation of Epidermal Structure: The Sulfur component exerts a keratolytic effect through local chemical transformation. Sulfur interacts with the cysteine content of keratin proteins to generate intermediate compounds, such as Hydrogen Sulfide ( H2 S), which chemically disrupts the structural disulfide bonds linking skin cells. This action promotes the accelerated loosening and shedding of the stratum corneum, which resolves structural blockages within the follicular ducts.

Synergistic Dual-Pathway Interruption: The core mechanism relies on synergy. Sulfacetamide addresses the biological driver by inhibiting microbial growth, while Sulfur addresses the structural driver by physically clearing occlusion. This simultaneous, two-pronged interruption of both the growth and mechanical components alters the local factors that influence physiological irritation and contributes to the regulation of epidermal cell turnover and surface microflora.

Dosage and Administration Information

How to Use SulfaCleanse: Administration Guidelines

SulfaCleanse (a combination of sulfacetamide and sulfur) is designed exclusively for topical administration; it must not be used internally or applied to the eyes (ophthalmic use). The standard administration protocol is based on the product’s formulation, which is commonly available as a wash, suspension, or lotion.


Dosing and Frequency Patterns

The typical regimen involves applying a liberal amount or a thin film of the product to the entire affected skin area, generally on a schedule of once daily or twice daily. The precise frequency is often managed to maintain skin comfort, allowing for adjustments to the usage (e.g., rinsing sooner or using less often) if excessive dryness occurs. The duration of use is often associated with the long-term management of chronic skin conditions.


Administration Procedure

For wash or suspension formulations, specific preparation and application steps are followed. The container must be shaken well before use, and the skin should be wetted prior to application. Users then gently massage the product into the skin for a specified period, typically 10 to 20 seconds, to work it into a lather. Following this step, the area must be rinsed thoroughly and patted dry.


Population Constraints

The safety and effectiveness of these formulations have not been established in pediatric patients under the age of 12. For older patients, the use protocol follows the standard adult dosing regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for SulfaCleanse

This section summarizes the types of clinical research that have examined SulfaCleanse (Sulfacetamide/Sulfur), detailing what outcomes were monitored and what remains uncertain in the evidence landscape, according to regulatory and peer-reviewed sources.


Evidence for use in Acne Vulgaris

SulfaCleanse was studied for acne vulgaris, a condition characterized by fluctuating or episodic manifestations. Randomized Controlled Trials (RCTs) have been conducted, with research examining how symptoms evolved in the observed populations over defined time intervals. Researchers primarily monitored outcomes related to inflammatory or irritative states, specifically the monitoring of the count of inflammatory lesions (papules and pustules), in adult and adolescent populations.

Research provides insight into short-term changes that were observed in some studies over follow-up periods that typically lasted up to 12 weeks. However, long-term effects are not fully established, and certainty remains low regarding durability. Furthermore, the evidence is limited by the fact that certain combination products are noted in official records as unapproved new drugs in some regulatory contexts, meaning they lack full governmental recognition of safety and effectiveness.


Evidence for use in Rosacea (Papulopustular/Inflammatory type)

SulfaCleanse was evaluated in studies related to the papulopustular form of rosacea, a condition characterized by fluctuating or episodic manifestations. The research examined outcomes linked to inflammatory or irritative states, including the assessment of the count of inflammatory lesions and assessments of facial erythema (redness). Findings indicate patterns related to changes in inflammatory lesions in the observed populations from short-term trials (e.g., 8 weeks).

However, the evidence quality varies across studies. Systematic reviews have noted that existing trials may be impacted by a high risk of bias, and certainty remains low when comparing these findings to other established treatments. The overall research base is often challenged by modest sample sizes and a reliance on short-term data, meaning comparative evidence is lacking against many modern topical therapies.

Key Studies & References

  1. The Use of Sodium Sulfacetamide in Dermatology (Review article covering Acne, Rosacea, and Seborrheic Dermatitis)
  2. SODIUM SULFACETAMIDE 10% AND SULFUR 5% CLEANSER (DailyMed Label for unapproved drug status and indications)

Frequently Asked Questions (FAQ)

Common questions about SulfaCleanse (FAQ)


Q: How fast can I expect to see results after starting SulfaCleanse?

According to official information, clinical trials for skin conditions like acne and rosacea often measure changes in symptoms over follow-up periods ranging from 8 to 12 weeks. This indicates that visible improvements may take several weeks to appear.


Q: Will using SulfaCleanse make my skin dry or flaky?

Yes, local skin effects like redness, irritation, and scaling (flakiness) are commonly reported adverse reactions associated with this topical combination. Regulatory information notes that official instructions often allow for usage adjustment, such as rinsing sooner or using less often, if excessive dryness occurs.


Q: Are there any specific foods or drinks I should avoid while on SulfaCleanse?

The official product labeling does not document any known adverse interactions with specific foods or beverages, including alcohol. Documented drug interactions for topical SulfaCleanse are primarily limited to other skin products.


Q: Is it okay to use makeup or moisturizer on top of SulfaCleanse?

Official patient information cautions that using other skin products simultaneously with SulfaCleanse may cause increased irritation. It is generally advised to consult with a healthcare professional before applying coverings, such as makeup or dressings, after using the medication.


Q: Can I use SulfaCleanse alongside other topical products?

Using other skin treatments at the same time as SulfaCleanse may increase skin irritation. Regulatory documents recommend consulting with a healthcare professional before combining SulfaCleanse with any other topical drugs or cosmetic products.


Q: Will SulfaCleanse make my skin peel?

The sulfur component of SulfaCleanse has a keratolytic effect, meaning it helps accelerate the shedding of the skin’s outer layer. Therefore, scaling (which users may describe as peeling) is listed as a common local adverse reaction.


Q: Is there a generic version of SulfaCleanse available?

The active ingredients in SulfaCleanse, sulfacetamide sodium and sulfur, are widely available as generic prescription topical products. However, regulatory bodies may note that some specific combination product formulations lack full therapeutic equivalency testing.


Q: Are the side effects of SulfaCleanse usually mild or severe?

The most common adverse effects, like stinging and irritation, are local and generally mild, with the total incidence documented as infrequent in clinical trials (typically less than 2%). However, the official warnings also describe rare but potentially fatal systemic effects linked to sulfonamide hypersensitivity.


Q: Does alcohol consumption affect how SulfaCleanse works?

The official product labeling for topical SulfaCleanse does not document any specific adverse interaction between the medication and the consumption of alcohol.


Q: Can SulfaCleanse cause sensitivity to the sun?

Official patient information often includes a caution that this medication may make your skin more sensitive to the sun. Official patient information generally includes advice to wear protective clothing and use sunscreen if sun exposure cannot be avoided.


Q: How long is a typical course of treatment with SulfaCleanse?

SulfaCleanse is commonly associated with the long-term management of chronic skin conditions. Treatment duration is determined by a healthcare provider and should not be used beyond the time period instructed.


Q: Does SulfaCleanse work better in the morning or at night?

The standard regimen involves applying the product once daily or twice daily. Regulatory documents do not specify a preferred time of day (morning or night) for optimal efficacy.


Q: Can SulfaCleanse cause any long-term health problems?

Long-term animal studies to evaluate the potential for cancer have not been performed, according to official labels. Patients are typically monitored for local irritation or sensitization during extended use.


Q: What should I do if I experience a severe allergic reaction to SulfaCleanse?

Official patient instructions indicate that in the event of signs of hypersensitivity or severe allergic reactions (such as blistering, peeling of the skin, hives, or swelling), the product must be immediately discontinued, and a healthcare professional should be promptly notified.


Q: Will SulfaCleanse stain my clothes or bedding?

Official patient information cautions that this medicine may stain clothing or fabric. Users are advised to take care to protect materials from contact with the product.


Q: Can I use SulfaCleanse if I have a history of liver or kidney problems?

SulfaCleanse is contraindicated (should not be used) in patients with known kidney disease (renal dysfunction). Therapy should be administered cautiously in patients who have a history of liver disease.


Q: Is SulfaCleanse an anti-inflammatory as well?

SulfaCleanse is formally classified as a topical anti-infective and a keratolytic agent. It is indicated for conditions characterized by inflammatory states and works by targeting bacterial growth and regulating skin cell turnover.


Q: Is SulfaCleanse absorbed into the bloodstream?

While absorption through intact skin has not been fully determined, official information states that significant systemic absorption has been reported in some cases. The risk of absorption is greater when the product is applied to large, infected, abraded, or compromised areas of skin.


Q: What are the signs that SulfaCleanse is starting to work?

Studies on the product primarily monitor for clinical outcomes such as a reduction in the count of inflammatory lesions (like papules and pustules). A decrease in these visible signs, along with any noted improvement in facial redness, is generally monitored as a sign of effectiveness.


Q: Is SulfaCleanse safe to use around the eyes or mouth?

Official administration instructions state that the product must be used externally and patients must avoid contact with eyes, eyelids, lips, and mucous membranes. If accidental contact occurs, the area must be thoroughly rinsed with water.

How should SulfaCleanse be stored and disposed of?

How to Store and Dispose of SulfaCleanse

SulfaCleanse (Sulfacetamide Sodium and Sulfur Topical) must be stored strictly according to official regulatory labeling to maintain its effectiveness and safety.


Official Storage Conditions

The product must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with minimal temperature excursions permitted. It is mandatory to protect the medication from freezing and excessive heat, and the container must be kept tightly closed when not in use. A slight darkening of the product during storage is noted in the labeling but does not impair its efficacy or safety. The medication must be kept out of the reach of children.

Disposal Requirements

Unused or expired SulfaCleanse should be properly disposed of by discarding it in the household trash, following local regulations for medication disposal. It is explicitly required that the product not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of SulfaCleanse found in:

A-Z Index: